SUMMARY Administration of 30 mg folic acid by mouth caused a significant fall in cerebrospinal fluid homovanillic acid concentration in 11 subjects. There was no significant change of 5-hydroxyindoleacetic acid concentration. The fall was less marked in five patients on anticonvulsant medication and failed to reach statistical significance. Neither homovanillic acid nor 5-hydroxyindoleacetic acid concentrations changed significantly when 15 mg folic acid was given in divided dosage for one, two, and four weeks. The effect appeared to be related to the height of serum-folate levels reached and to be independent of cerebrospinal fluid-folate levels, which did not change significantly. Possible mechanisms and their potential therapeutic application are discussed.
It has been reported that folic acid given by mouth in pharmacological doses may cause nervous and gastrointestinal symptoms in some healthy subjects (Hunter, Barnes, Oakeley, and Matthews, 1970) . It was suggested that this effect resulted from high tissue levels of folate interfering with brain-amine metabolism for which a reduced folic acid derivative is known to be a cofactor (Blakley, 1969) . We therefore investigated the effect of folic acid on cerebrospinal fluid (CSF) homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA) levels, since there is evidence that these provide a measure of turnover of the amines dopamine and 5-hydroxytryptamine in the brain (Bowers and Gerbode, 1968; Guldberg, 1969) .
METHODS
Volunteers were informal patients in a psychiatric hospital and were capable of informed consent. Thirtyfour participated, 29 men and five women. Their ages ranged from 25 to 64 years with a mean of 44. All were ambulant and on full diet. Apart from five epileptic patients on an anticonvulsant regime of phenobarbitone and phenytoin, subjects required no drugs other than occasional hypnotics. Preliminary examination of peripheral blood and serum-vitamin-B12 levels gave results within the normal range.
All lumbar punctures were performed at the same time two hours after breakfast under local anaesthesia with subjects in the lateral recumbent position and premedicated two hours before with 300 mg amylobarbitone sodium. Blood was taken simultaneously for serumfolate estimation. Minimum interval between punctures was two weeks.
Serum-and CSF-folate was estimated by the method of Waters and Mollin (1961) using Lactobacillus casei. CSF HVA was determined by a modified combination of the methods of And6n, Roos, and Werdinius (1963) and Murphy, Robinson, and Sharman (1969) described previously (Curzon, Godwin-Austen, Tomlinson, and Kantamaneni, 1970) ,and 5-HIAAbyamodificationof the procedure of Korf and Valkenburgh-Sikkema (1969) .
After initial estimation of CSF HVA and 5-HIAA and serum-and CSF-folate, subjects were divided into six groups. In group 1 (11 subjects) and group 2 (five epileptics) repeat estimations were made two weeks later and four hours after a single oral dose of 30 mg folic acid. Group 3 (n = 6) acted as controls and estimations were repeated after two weeks without prior administration of folic acid. In group 4 (n = 6 of whom four had also participated in group 1), group five (n = 5), and group six (n = 5) estimations were repeated after they had received 15 mg folic acid daily in divided dosage for one, two, and four weeks respectively. In the eight subjects in whom the estimation was performed mean 5-HIAA concentration also fell but not significantly (Table 2 and Fig. 1 ). There was also a significant fall in HVA: 5-HIAA ratio from 1-51 to 0-82 (P < 0-05). Serum-folate rose substantially but CSF-folate remained unchanged in eight subjects in whom this estimation was done (Table 1) 
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.oloo L group.bmj.com on June 21, 2017 -Published by http://jnnp.bmj.com/ Downloaded from tration and so by implication affect the metabolism in the brain of its precursor dopamine. The alternative possibility that folate affects transport of HVA either from brain to CSF or from CSF to blood is not excluded.
Epileptic patients showed only a small fall of HVA which was not significant. Presumably this was related to the much smaller rise of serum-folate observed in them than in the other subjects given 30 mg folic acid who were not on an anticonvulsant regime. Such drugs are known to interfere with the absorption of folate from the gut (Chanarin, 1969; Benn, Swan, Cooke, Blair, Matty, and Smith, 1971 ).
In groups 4, 5, and 6 administration of 15 mg folic acid daily in divided dosage for one, two, and four weeks respectively did not cause a significant change of HVA or 5-HIAA concentrations. This lack of effect correlated with still smaller increments of serum-folate in groups 5 and 6 for whom results are available than that observed in epileptic patients given a single 30 mg dose.
Mean HVA concentration for all subjects in this series taken together before administration of folic acid was significantly lower than that of a group of patients with miscellaneous neurological conditions already referred to and approximated that of a group of patients with Parkinsonism. This may reflect the high incidence of extrapyramidal disorders (Jones and Hunter, 1969) and cerebral atrophic conditions (Hunter, Jones, and Cooper, 1968) found in patients with persistent or disabling mental symptoms. Conceivably differences in procedures for taking CSFmay also have played a part, since the three series of patients were examined in different hospitals.
One possible mechanism for the effect of folic acid on CSF HVA levels is suggested by the in vitro requirement of 5,6,7,8-tetrahydrofolic acid as a cofactor for catecholamine (Kaufman, 1963; Nagatsu, Levitt, and Udenfriend, 1964) and 5-hydroxytryptamine (Gal, Armstrong, and Ginsberg, 1966) synthesis. This cofactor may be formed by reduction of 7,8-dihydrofolic acid through the action of dihydrofolic acid reductase. Folic acid is a competitive inhibitor of this enzyme (Bertino, Perkins, and Johns, 1965) , though its action is much weaker than that of folate analogues in clinical use. Blair (1970) (1970) who found that when mice were injected with 300 mg folic acid per kilogram body weight their kidney dihydrofolic acid reductase activity fell by 80% within 10 minutes and that low activity persisted for 72 hours. Clearly a similar inhibition may also lead to reduced dopamine synthesis and hence decreased formation of its metabolite HVA.
The decrease of CSF HVA after a single dose of 30 mg folic acid does not explain the toxic or alerting effects of daily administration of 15 mg folic acid, since in the present investigation this dose was not associated with HVA change. Increased dopamine turnover after L-dopa administration may cause alerting (Blaschko and Chrusciel, 1960) but also increases CSF HVA (Curzon et al., 1970) . However, HVA formation requires two enzymes (Axelrod, 1966) , the intraneuronal monoamine oxidase and the extraneuronal catecholamine-O-methyl transferase. Impaired extraneuronal metabolism of dopamine in the presence of normal neuronal release would lead to increased dopamine effect at receptor sites and low CSF HVA concentration. In these circumstances alerting might occur. Such a mechanism would be consistent with folic acid causing a fall of HVA without a significant effect on 5-HIAA levels since, although both catecholamine and 5-hydroxytryptamine synthesis require tetrahydrofolic acid, 0-methyl transferase is involved in catecholamine metabolism only.
If this explanation is correct, it implies a possible effect of folic acid supplement on dyskinetic syndromes. Parkinsonism is associated with decreased brain dopamine synthesis (Hornykiewicz, 1963) and one suggested mechanism of Huntington's chorea is increased sensitivity of dopamine receptors (Klawans, Paulson, and Barbeau, 1970) . Therefore if folic acid impairs dopamine synthesis, its administration might be expected to exacerbate Parkinsonism and possibly have a beneficial effect on the manifestations of Huntington's chorea. The opposite effects should occur if the low HVA levels caused by folic acid are due to impaired extraneuronal dopamine destruction.
Folic acid administration has occasionally been reported to cause fits in patients with megaloblastic anaemia due either to anticonvulsant medication (Chanarin, Laidlaw, Loughridge, and Mollin, 1960; Reynolds, Chanarin, and Matthews, 1968) or folate absorption defect (Lanzkowsky et al., 1969) . There has been no satisfactory explanation of this rare complication (Richens, 1971) . Folic acid has also been observed to cause convulsions in rats when given by intraventricular injection in a dose of 2-2 ,g (Noell, Magoss, Cohen, Holland, and Walters, 1960) . Generalized synchronous spikes were recorded within 10 minutes followed by 'cortical seizures' lasting several hours.
It may be that subjects with low dihydrofolic acid 
